<unk>  (known formerly as WF-516) is an investigational antidepressant which is under development by<unk> erva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015,<unk>  is in phase II clinical trials for MDD. In December 2019,<unk> erva announced that<unk>  was no longer in clinical development for MDD after disappointing results in a phase IIb trial.
MIN-117
RGC100
MCN
CARB-X
BIM-1
ONCOS-102
ARCT-154
BGR-34